The association between longitudinal trends in receipt of buprenorphine for opioid use disorder and buprenorphine-waivered providers in the United States.

Aims, Design and Setting: We sought to describe longitudinal trends in buprenorphine receipt and buprenorphine-waivered providers in the United States from 2003 to 2021 and measure whether the relationship between the two differed after capacity-building strategies were enacted nationally in 2017. T...

Descripción completa

Detalles Bibliográficos
Publicado en:Addiction Vol. 118; no. 11; pp. 2215 - 2220
Autores principales: Stringfellow, Erin J., Tse Yang Lim, Huiru Dong, Ziyuan Zhang, Jalali, Mohammad S.
Formato: research tables/charts Journal Article
Publicado: Wiley-Blackwell Nov2023
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=173385897&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 173385897
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        09652140
        AIO
      jtl: Addiction
      issn: 09652140
      maglogo: Y
    pubinfo:
      dt: Nov2023
      vid: 118
      iid: 11
      pid: 480
      pub: Wiley-Blackwell
      place: Malden, Massachusetts
    artinfo:
      ui:
        173385897
        164809357
        173385897
        173385897
        10.1111/add.16291
        173385897
      ppf: 2215
      ppct: 5
      formats:
        fmt:
          @attributes:
            type: P
      tig:
        atl: The association between longitudinal trends in receipt of buprenorphine for opioid use disorder and buprenorphine-waivered providers in the United States.
      aug:
        au:
          Stringfellow, Erin J.
          Tse Yang Lim
          Huiru Dong
          Ziyuan Zhang
          Jalali, Mohammad S.
        affil: Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
      sug:
        subj:
          Substance Use Disorders Drug Therapy
          Buprenorphine Therapeutic Use
          Mental Health Personnel Trends
          Attitude of Health Personnel
          Prescriptions, Drug
          Psychiatric Patients
          Human
          Male
          Female
          Retrospective Design
          Prospective Studies
          United States
          Data Analysis Software
          Confidence Intervals
          Comparative Studies
          Funding Source
          Male
          Female
      ab: Aims, Design and Setting: We sought to describe longitudinal trends in buprenorphine receipt and buprenorphine-waivered providers in the United States from 2003 to 2021 and measure whether the relationship between the two differed after capacity-building strategies were enacted nationally in 2017. This was a retrospective study of two separate cohorts covering the years 2003-21, testing whether the association between two trends in these cohorts changed comparing 2003 to 2016 and from 2017 to 2021, among buprenorphine providers in the United States, regardless of treatment setting. Patients receiving dispensed buprenorphine at retail pharmacies. Participants: All providers who have obtained a waiver to prescribe buprenorphine in the United States, and an estimate of the annual number of patients who had buprenorphine for opioid use disorder (OUD) dispensed to them at a retail pharmacy. Measurements: We synthesized and summarized data from multiple sources to assess the cumulative number of buprenorphine-waivered providers over time. We used national-level prescription data from IQVIA to estimate annual buprenorphine receipt for OUD. Findings: From 2003 to 2021, the number of buprenorphine-waivered providers in the United States increased from fewer than 5000 in the first 2 years of Food and Drug Administration (FDA) approval to more than 114 000 in 2021, while patients receiving buprenorphine products for OUD increased from approximately 19 000 to more than 1.4 million. The strength of association between waivered providers and patients is significantly different before and after 2017 (P < 0.001). From 2003 to 2016, for each additional provider, there was an average increase of 32.1 [95% confidence interval (CI) = 28.7-35.6] patients, but an increase of only 4.6 (95% CI= 3.5-5.7) patients for each additional provider, beginning in 2017. Conclusions: In the United States, the relationship between the rates of growth in buprenorphine providers and patients became weaker after 2017. While efforts to increase buprenorphine-waivered providers were successful, there was less success in translating that into significant increases in buprenorphine receipt.
      pubtype: Academic Journal
      doctype:
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N